Cipher Pharmaceuticals Reports First Quarter Results

Cipher Pharmaceuticals reported first‑quarter 2026 financial results after the close on May 7. Net income soared 135% year‑over‑year to $6.2 million, producing basic EPS of $0.24. Adjusted EBITDA rose 25% to $7.7 million on revenue of $12.5 million, a modest 4% gain. Licensing revenue jumped 52% while the flagship Natroba™ topical product grew just 3% to $6.9 million. The Canadian portfolio slipped 2%. Gross margin expanded to 82% and SG&A was slashed 42%. The company fully repaid its revolving credit facility, leaving a $6.4 million cash balance and $65 million of undrawn capacity (plus a $25 million accordion). Management reiterated a focus on business development, with Health Canada’s New Drug Submission for Natroba under review. Separately, the TSX approved a new Normal Course Issuer Bid to repurchase up to 1,490,343 shares over the next twelve months.

The Q1 release is a routine positive update. Strong profit growth stems largely from cost-cutting and a one‑time licensing bump, not from accelerating top‑line momentum. Natroba revenue was essentially flat sequentially and grew only 3% year‑over‑year, showing the core U.S. franchise is maturing. Full repayment of the revolver was well telegraphed; after $35 million in FY2025 repayments, the market expected the remaining $5 million to be wiped out. The announcement changes nothing about the fundamental investment thesis – the story remains a well‑capitalized specialty pharma company seeking an acquisition catalyst. The NCIB is a minor capital‑allocation tool, not a value driver. No new product approvals, licensing deals, or M&A targets were disclosed. Consequently, the market’s reaction was muted; the stock was trading at $17.87 on the day, roughly in line with recent levels, and there was no post‑earnings gap.

Cipher Pharmaceuticals is a specialty pharmaceutical company with products marketed in the U.S., Canada, and South America. Its flagship asset is Natroba™ (spinosad), a single‑application topical treatment for head lice and scabies. Cipher acquired the U.S. rights to Natroba in July 2024 and has focused on expanding its U.S. market share, obtaining preferred step‑through status on Illinois Medicaid, and pursuing Canadian approval. The company also markets a portfolio of branded products in Canada – notably Epuris for severe acne – and earns licensing revenue from legacy out‑licensed assets.